6 January 2022

New collaboration with RefLab shows beneficial properties of lead candidate epidermicin NI01 for topical skin therapy

by Mathew Upton

January 2022

Amprologix and RefLab ApS (Copenhagen, Denmark) have collaborated on a project using an ex vivo human skin microdialysis model (below) to test pseudo-allergic reactions in the skin, without using animal models. 

Amprologix and RefLab ApS (Copenhagen, Denmark) have collaborated on a project using an ex vivo human skin microdialysis model (below) to test pseudo-allergic reactions in the skin, without using animal models. Data clearly demonstrated that lead candidate epidermicin NI01 does not have any pseudo-allergic liabilities, consistent with its wider performance in pre-clinical toxicology tests. This is in stark contrast to some peptide-based antimicrobials, which have failed pre-clinical workup due to stimulation of allergic responses.
 
Working with ex-vivo human skin gives good confidence that future applications to humans will be a safe and efficacious way to treat skin infections caused by leading pathogens like MRSA.
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram